Poxel Sa Stock Fundamentals

POXEL Stock  EUR 0.23  0.00  0.00%   
Poxel SA fundamentals help investors to digest information that contributes to Poxel SA's financial success or failures. It also enables traders to predict the movement of Poxel Stock. The fundamental analysis module provides a way to measure Poxel SA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Poxel SA stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Poxel SA Company Return On Equity Analysis

Poxel SA's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Poxel SA Return On Equity

    
  -3.23  
Most of Poxel SA's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Poxel SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Poxel SA has a Return On Equity of -3.2337. This is 86.51% lower than that of the Biotechnology sector and 91.13% lower than that of the Health Care industry. The return on equity for all France stocks is notably higher than that of the company.

Poxel SA Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Poxel SA's current stock value. Our valuation model uses many indicators to compare Poxel SA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Poxel SA competition to find correlations between indicators driving Poxel SA's intrinsic value. More Info.
Poxel SA is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Poxel SA's earnings, one of the primary drivers of an investment's value.

Poxel Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Poxel SA's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Poxel SA could also be used in its relative valuation, which is a method of valuing Poxel SA by comparing valuation metrics of similar companies.
Poxel SA is currently under evaluation in return on equity category among its peers.

Poxel Fundamentals

About Poxel SA Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Poxel SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Poxel SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Poxel SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Poxel SA, a biopharmaceutical company, develops drugs for metabolic diseases with a primary focus on type II diabetes. The company was founded in 2009 and is headquartered in Lyon, France. Poxel SA operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 33 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Poxel Stock Analysis

When running Poxel SA's price analysis, check to measure Poxel SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poxel SA is operating at the current time. Most of Poxel SA's value examination focuses on studying past and present price action to predict the probability of Poxel SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poxel SA's price. Additionally, you may evaluate how the addition of Poxel SA to your portfolios can decrease your overall portfolio volatility.